Greetings, and humble apologies for the hiatus of this blog – have not forgotten about all of you, but it’s been a crazy year in the world of sarcomas. I’m so excited to share with you some of the highlights of ASCO, where nearly 40,000 medical oncologists and other cancer research aficionados gather yearly to present … More Updates from ASCO 2017 Annual Meeting
Greetings from Chicago, where once again, immunotherapy remains the highlight of most ASCO presentations. This year was particularly exciting, as we finally got to see the preliminary results of the first clinical trials of checkpoint inhibitors for sarcomas. So, I will update all of you on the most recent data, explain how we still have more … More Updates from ASCO 2016: Immunotherapy for sarcoma shows a signal!
This is a guinea pig. Greetings readers, My 282 page grant finally went in Monday – and so now I finally have some spare writing quota to return to the blog! Today’s topic – everything you ever needed to know about clinical trials. The goal is to clear up some misconceptions, and also to help … More Clinical Trials: What you should know to make an informed choice about your therapy.
Borrowed from Chakma J. Genomic Variation: The Search for our Past and Our Future. Journal of Young Investigators. Vol 16, 2009. The White House Initiative The concept of personalized medicine has received a tremendous amount of media attention as of late, and in this post I thought I would try to outline the various technologies, concepts, … More have we really reached the era of personalized medicine?
In honor of the 4th of July holiday, I thought I’d squeeze in one more post – let’s talk about IMMUNOTHERAPY, which has created fireworks of its own in the cancer treatment world! In order to talk about the exciting clinical trials and ideas that are out there for sarcoma patients, we need to first … More Immunotherapy 101
A lot of people ask me why I take care of sarcoma patients – no one knows what they are (except for all of you kind readers who are now experts!), there’s no good data, certainly no major funding opportunities, and we’re still using the same chemotherapy drugs that we have used since 1970s… not … More why sarcoma?